Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Oral Oncology

• Publication date

  2016-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.oraloncology.2016.05.008PMID 27264839PMCID PMC5264518
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.

  2016cited by this paper
• Comprehensive genomic characterization of head and neck squamous cell carcinomas

  2015cited by this paper
• STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients

  2015cited by this paper
• Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy*

  2015cited by this paper
• MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.

  2013cited by this paper
• EGFR-mediated tumor immunoescape

  2013cited by this paper
• Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients

  2013cited by this paper
• SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells

  2013cited by this paper
• Cross-presentation by dendritic cells

  2012cited by this paper
• The endosome–lysosome pathway and information generation in the immune system

  2012cited by this paper
• Post-Transcriptional and Epigenetic Regulation of Antigen Processing Machinery (APM) Components and HLA-I in Cervical Cancers from Uighur Women

  2012cited by this paper
• Expression of antigen processing and presenting molecules in brain metastasis of breast cancer

  2012cited by this paper
• Comprehensive genomic characterization of squamous cell lung cancers

  2012cited by this paper
• Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting.

  2012cited by this paper
• Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer.

  2011cited by this paper
• Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics.

  2011cited by this paper
• Association of IFN-γ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines

  2011cited by this paper
• Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas

  2010cited by this paper
• Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer

  2010cited by this paper
• ABC proteins in antigen translocation and viral inhibition.

  2010cited by this paper
• Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma.

  2010cited by this paper
• HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis.

  2010cited by this paper
• Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: Association with disease progression

  2009cited by this paper
• Downregulation of HLA class I molecules in primary oral squamous cell carcinomas and cell lines.

  2009cited by this paper
• MUTYH‐associated polyposis carcinomas frequently lose HLA class I expression—a common event amongst DNA‐repair‐deficient colorectal cancers

  2009cited by this paper
• Molecular mechanisms of MHC class I abnormalities and APM components in human tumors

  2008cited by this paper
• HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma

  2008cited by this paper
• Loss of expression of antigen‐presenting molecules in human pancreatic cancer and pancreatic cancer cell lines

  2007cited by this paper
• HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression

  2007cited by this paper
• Characterization of the immune escape phenotype of human gastric cancers with and without high‐frequency microsatellite instability

  2007cited by this paper
• Genetic variation of antigen processing machinery components and association with cervical carcinoma

  2007cited by this paper
• Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms.

  2007cited by this paper
• Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.

  2006cited by this paper
• Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL1

  2006cited by this paper
• HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.

  2006cited by this paper
• Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer

  2006cited by this paper
• Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection.

  2006cited by this paper
• Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis.

  2005cited by this paper
• Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.

  2005cited by this paper
• Human leukocyte antigen (HLA) class I defects in head and neck cancer

  2005cited by this paper
• Coordinated downregulation of the antigen presentation machinery and HLA class I/β2‐microglobulin complex is responsible for HLA‐ABC loss in bladder cancer

  2005cited by this paper
• Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome

  2005cited by this paper
• Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis.

  2005cited by this paper
• Mechanisms of tumor evasion.

  2005cited by this paper
• Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers.

  2005cited by this paper
• Cancer Immunotherapy: A Treatment for the Masses

  2004cited by this paper
• HLA Antigen Changes in Malignant Tumors of Mammary Epithelial Origin: Molecular Mechanisms and Clinical Implications

  2004cited by this paper
• MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma

  2004cited by this paper
• The ATP switch model for ABC transporters

  2004cited by this paper
• Animal models of tumor immunity, immunotherapy and cancer vaccines.

  2004cited by this paper
• Mutations in TAP genes are common in cervical carcinomas.

  2004cited by this paper
• Development of effective immunotherapy for the treatment of patients with cancer.

  2004cited by this paper
• A Single-nucleotide Deletion Leads to Rapid Degradation ofTAP-1 mRNA in a Melanoma Cell Line*

  2003cited by this paper
• Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor Signaling

  2003cited by this paper
• Antigen processing and recognition.

  2003cited by this paper
• Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients.

  2003cited by this paper
• Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression

  2003cited by this paper
• Tumors as elusive targets of T-cell-based active immunotherapy.

  2003cited by this paper
• HLA class I antigen abnormalities and immune escape by malignant cells.

  2002cited by this paper
• Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21

  2002cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• TAP1 down‐regulation in primary melanoma lesions: An independent marker of poor prognosis

  2001cited by this paper
• Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products

  2001cited by this paper
• Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.

  2001cited by this paper
• Use of chimeric proteins to investigate the role of transporter associated with antigen processing (TAP) structural domains in peptide binding and translocation

  2001cited by this paper
• Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing.

  2001cited by this paper
• Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.

  2000cited by this paper
• High frequency of altered HLA class I phenotypes in laryngeal carcinomas.

  2000cited by this paper
• Loss of Interferon-γ Inducibility of TAP1 and LMP2 in a Renal Cell Carcinoma Cell Line

  2000cited by this paper
• Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features.

  1999cited by this paper
• A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly.

  1999cited by this paper
• HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas.

  1999cited by this paper
• Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.

  1999cited by this paper
• Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line .220.

  1998cited by this paper
• Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell‐mediated immune recognition of human melanoma cells

  1998cited by this paper
• Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis.

  1998cited by this paper
• Interferon-γ Rapidly Increases Peptide Transporter (TAP) Subunit Expression and Peptide Transport Capacity in Endothelial Cells*

  1997cited by this paper
• Regulation of MHC class I heterodimer stability and interaction with TAP by tapasin

  1997cited by this paper
• High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas.

  1996cited by this paper
• A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer

  1996cited by this paper
• MHC class I/beta 2-microglobulin complexes associate with TAP transporters before peptide binding.

  1994cited by this paper
• Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7.

  1994cited by this paper
• MHC class l/β2-microglobulin complexes associate with TAP transporters before peptide binding

  1994cited by this paper
• Interferon-gamma induces different subunit organizations and functional diversity of proteasomes.

  1994cited by this paper
• [Patients with limited life possibilities (1): support of cancer patients. Interactions with patients who suspected cancer].

  1984cited by this paper

• Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies

  2025cites this paper
• The regulatory role and mechanism of energy metabolism and immune response in head and neck cancer

  2025cites this paper
• Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma

  2025cites this paper
• Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers

  2024cites this paper
• Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway

  2024cites this paper
• Developing and validating the model of tumor-infiltrating immune cell to predict survival in patients receiving radiation therapy for head and neck squamous cell carcinoma

  2024cites this paper
• Immunotherapy for head and neck cancer: Fundamentals and therapeutic development.

  2024cites this paper
• Neoadjuvante Immuntherapie bei Kopf-Hals- Plattenepithelkarzinomen

  2024cites this paper
• Pervasiveness of HLA allele-specific expression loss across tumor types

  2023cites this paper
• Curcuphenol possesses an unusual histone deacetylase enhancing activity that counters immune escape in metastatic tumours

  2023cites this paper
• Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer

  2023cites this paper
• Editorial: Lymphocyte functional crosstalk and regulation, volume II

  2023cites this paper
• Construction of a non-negative matrix factorization model of immunogenic cell death-related genes in lung adenocarcinoma and analysis of survival prognosis.

  2023cites this paper
• Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas

  2022cites this paper
• Novel cellular therapies for hepatobiliary malignancies.

  2022cites this paper
• Cancer immunotherapy: diverse approaches and obstacles.

  2022cites this paper
• Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers

  2022cites this paper
• Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer

  2021cites this paper
• Tumor-Infiltrating Lymphocytes in Patients With Advanced Laryngeal Cancer Undergoing Bioselection

  2021cites this paper
• Clustering of Major Histocompatibility Complex-Class I Molecules in Healthy and Cancer Colon Cells Revealed from Their Nanomechanical Properties.

  2021cites this paper
• Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer

  2021cites this paper
• Epigenetic modulation of immunotherapy and implications in head and neck cancer

  2021cites this paper
• Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma

  2021cites this paper
• Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists

  2021cites this paper
• Bioinformatics analysis identified shared differentially expressed genes as potential biomarkers for Hashimoto's thyroiditis-related papillary thyroid cancer

  2021cites this paper
• Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.

  2021cites this paper
• Tumoral HLA Class I and APM Expression and Its Effect on Intratumoral T-cell Reaction and Outcome in HPV-Negative Oral Squamous Cell Carcinoma

  2020cites this paper
• Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

  2020cites this paper
• HLA allele-specific expression loss in tumors can shorten survival and hinder immunotherapy

  2020cites this paper
• Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients

  2020cites this paper
• Combining Radiotherapy and Immunotherapy in Definitive Treatment of Head and Neck Squamous Cell Carcinoma: Review of Current Clinical Trials

  2020cites this paper
• Expression of NK cell receptor ligands in primary colorectal cancer tissue in relation to the phenotype of circulating NK- and NKT cells, and clinical outcome.

  2020cites this paper
• Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer

  2020cites this paper
• The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design

  2020cites this paper
• The Microenvironment of Tongue Cancer.

  2020cites this paper
• Death and the Miser: microbiota regulate the outcome of checkpoint inhibition immunotherapy

  2019cites this paper
• Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma

  2019cites this paper
• Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung

  2019influential citation
• Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy.

  2019cites this paper
• Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti–PD-1 Resistance in Head and Neck Cancer

  2019cites this paper
• Frozen Cytology of CNS Neoplasm

  2019cites this paper
• Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B

  2019cites this paper
• Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations.

  2019cites this paper
• Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source.

  2019cites this paper
• Novel Immunotherapeutic Approaches in Head and Neck Cancer.

  2019cites this paper
• Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.

  2018cites this paper
• Prostate cancer health disparities: An immuno-biological perspective.

  2018cites this paper
• Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)

  2018cites this paper
• Influence de la lymphopénie sur la réponse au Cetuximab en première ligne de chimiothérapie palliative dans les carcinomes épidermoïdes des VADS

  2018cites this paper
• DNA Vaccines—How Far From Clinical Use?

  2018influential citation
• Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.

  2018cites this paper
• Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer

  2018cites this paper
• Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28–29 2017, Doha, Qatar)

  2018cites this paper
• Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges

  2018cites this paper
• Oncolytic viruses as engineering platforms for combination immunotherapy

  2018cites this paper
• Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting

  2017influential citation
• Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.

  2017cites this paper
• Induction of the antigen presentation machinery using novel small molecules

  2017cites this paper
• Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.

  2017cites this paper
• Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy

  2017cites this paper
• Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model

  2016cites this paper
• Molecular mechanisms of HLA class I‐mediated immune evasion of human tumors and their role in resistance to immunotherapies

  2016cites this paper
• CELL LINE Establishment and characterization of a novel hypopharyngeal squamous cell carcinoma cell line CZH1 with genetic abnormalities

  year unknowncites this paper